Even after raising $100 million, the biotech company remains focused on limiting cash burn. Seattle-based Umoja Biopharma is trying to stay lean after a $100 million Series C round announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback